Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

NCT06050928 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
33
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Escient Pharmaceuticals, Inc